MannKind, United Therapeutics Jump as Inhaler Gets FDA Nod

 MannKind and United Therapeutics both surge after the FDA approved their Tyvaso DPI product for lung disease.

• The FDA says that the inhaler’s potential pulmonary risks “are adequately characterized” by available data and addressed in the product’s label
• FDA said it was approved to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in a letter rejecting a Citizen’s Petition requesting the agency not to approve the inhaler combo

https://news.bloomberglaw.com/pharma-and-life-sciences/mannkind-united-therapeutics-jump-as-inhaler-gets-fda-nod-1